Matthew herder

Biography

Dr. MATTHEW HERDER is affiliated to , Dalhousie University. Dr. MATTHEW HERDER is currently providing services as Director, Health Law Institute; Associate Professor of Medicine. Dr. MATTHEW HERDER has authored I145and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. MATTHEW HERDER contributions have acclaimed recognition from honourable subject experts around the world. Dr. MATTHEW HERDER is actively associated with different societies and academies. Dr. MATTHEW HERDER academic career is decorated with several reputed awards and funding. Dr. MATTHEW HERDER research interests include Professor Herder’s research interests cluster around biomedical innovation policy, with particular focus on intellectual property law and practices connected to the commercialization of scientific research. As part of a three-year research project funded by the Canadian Institutes of Health Research, Professor Herder (Principal Investigator) and a team of interdisciplinary researchers are currently collecting empirical evidence about the inter-relationships between commercialization laws, policies, and practices and emerging health researchers. The team will use the collected empirical evidence to explore a series of normative questions about the ongoing commercialization of academic science..

Research Interest

Professor Herder’s research interests cluster around biomedical innovation policy, with particular focus on intellectual property law and practices connected to the commercialization of scientific research. As part of a three-year research project funded by the Canadian Institutes of Health Research, Professor Herder (Principal Investigator) and a team of interdisciplinary researchers are currently collecting empirical evidence about the inter-relationships between commercialization laws, policies, and practices and emerging health researchers. The team will use the collected empirical evidence to explore a series of normative questions about the ongoing commercialization of academic science.